甲状腺未分化癌诊疗指南总结与靶向治疗研究.pptVIP

Nature Reviews Endocrinology, 2017. Distribution of oncogenic alterations in anaplastic thyroid carcinoma. Nature Reviews Endocrinology, 2017. Imatinib：治疗后复发，II期研究， 400 mg orally twice daily， treatment responses were assessed every 8?weeks， 6-month progression-free survival (PFS) was 36% and the 6-month OS was 45% Pazopanib：II期，16例，无反应；另一项入组中，October?2018结束 Vemurafenib： twice-daily oral dose of 960 mg，1例15岁患者效果显著 Everolimus： single-arm phase?II trial，6/40例 ATC，PFS was 10?weeks (95%?CI 4.8–16.0) and OS was 13?weeks (95%?CI 7.4–18.6) in patients with ATC Nature Reviews Endocrinology, 2017. G